The number of tested samples has increased significantly from a daily average of 230k during the first week of July '20 to over two million daily samples tested in May with the ongoing second wave of the pandemic which began in India in March '21. The COVID-19 vaccination programme in India commenced on Jan 16th '21 with approx. 224 million vaccine doses administered up to Jun 4 (for more information on vaccination status, refer to the embedded report above). Three vaccines have so far been approved, ie Covashield (developed by Oxford-AstraZeneca) manufactured by Serum Institure of India, Covaxin (developed by Bharat Biotech in collaboration with ICMR) manufactured by Bharat Biotech and Sputnik V (Gam-COVID-Vac) developed by Russia's Gamaleya National Centre of Epidemiology and Microbiology. Other COVID-19 vaccines that are in the regulator approval pipeline and/or at an advanced vaccine trial stage include the ZyCoV-D plasmid DNA vaccine developed by Zydus Cadila, Serum Institute of India's Novavax vaccine, Bharat Biotech's intranasal vaccine and Gennova Biopharmaceuricals' mRNA vaccine.